PL3039038T3 - Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania - Google Patents

Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania

Info

Publication number
PL3039038T3
PL3039038T3 PL14839630T PL14839630T PL3039038T3 PL 3039038 T3 PL3039038 T3 PL 3039038T3 PL 14839630 T PL14839630 T PL 14839630T PL 14839630 T PL14839630 T PL 14839630T PL 3039038 T3 PL3039038 T3 PL 3039038T3
Authority
PL
Poland
Prior art keywords
serum albumin
preparing method
fusion construct
effector moiety
anti serum
Prior art date
Application number
PL14839630T
Other languages
English (en)
Polish (pl)
Inventor
Sanghoon Cha
Original Assignee
Aprilbio Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co., Ltd filed Critical Aprilbio Co., Ltd
Publication of PL3039038T3 publication Critical patent/PL3039038T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
PL14839630T 2013-08-30 2014-08-29 Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania PL3039038T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
EP14839630.2A EP3039038B1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Publications (1)

Publication Number Publication Date
PL3039038T3 true PL3039038T3 (pl) 2021-04-19

Family

ID=52586989

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14839630T PL3039038T3 (pl) 2013-08-30 2014-08-29 Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania

Country Status (16)

Country Link
US (2) US9879077B2 (https=)
EP (2) EP3039038B1 (https=)
JP (2) JP6422977B2 (https=)
KR (2) KR101576561B1 (https=)
CN (1) CN105899532B (https=)
AU (1) AU2014312456B2 (https=)
BR (1) BR112016004355A2 (https=)
CA (1) CA2922618C (https=)
DK (1) DK3039038T3 (https=)
ES (1) ES2866848T3 (https=)
MX (1) MX371328B (https=)
PH (1) PH12016500403A1 (https=)
PL (1) PL3039038T3 (https=)
RU (1) RU2661087C2 (https=)
UA (1) UA117493C2 (https=)
WO (1) WO2015030539A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN119343367A (zh) * 2022-06-15 2025-01-21 Ucb生物制药有限责任公司 卵泡抑素融合蛋白
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
WO2025253161A1 (en) * 2024-06-05 2025-12-11 Aprilbio Co., Ltd. Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
TW200607523A (en) * 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
MX2007003907A (es) * 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
RU2411957C2 (ru) 2004-12-02 2011-02-20 Домантис Лимитед Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1
JP5142707B2 (ja) * 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 抗体の改良方法
AU2008261042A1 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
EP2535349A1 (en) * 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
WO2011015649A1 (en) * 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CN104147611A (zh) * 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013068571A1 (en) * 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof

Also Published As

Publication number Publication date
US9879077B2 (en) 2018-01-30
US20180030127A1 (en) 2018-02-01
CA2922618A1 (en) 2015-03-05
KR20150118565A (ko) 2015-10-22
CN105899532A (zh) 2016-08-24
EP3632930A1 (en) 2020-04-08
BR112016004355A2 (pt) 2017-10-17
RU2016105586A (ru) 2017-10-04
CN105899532B (zh) 2021-10-08
AU2014312456A8 (en) 2016-03-17
DK3039038T3 (da) 2021-02-08
JP2016528922A (ja) 2016-09-23
CA2922618C (en) 2020-04-28
MX371328B (es) 2020-01-27
US10618953B2 (en) 2020-04-14
KR101576561B1 (ko) 2015-12-10
ES2866848T3 (es) 2021-10-19
EP3039038A4 (en) 2017-07-05
EP3039038A1 (en) 2016-07-06
HK1223107A1 (zh) 2017-07-21
JP6800180B2 (ja) 2020-12-16
KR20150026997A (ko) 2015-03-11
MX2016002539A (es) 2016-10-13
JP6422977B2 (ja) 2018-11-14
UA117493C2 (uk) 2018-08-10
PH12016500403A1 (en) 2016-05-16
JP2018172391A (ja) 2018-11-08
RU2661087C2 (ru) 2018-07-11
EP3039038B1 (en) 2020-11-25
AU2014312456B2 (en) 2017-07-06
WO2015030539A1 (en) 2015-03-05
AU2014312456A1 (en) 2016-03-03
US20160376350A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
PL3039038T3 (pl) Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania
PH12020551846A1 (en) An absorbent composite, methods for making the absorbent composite, and an absorbent article employing the same
SG11201603037WA (en) Composite material, heat-absorbing component, and method for producing the composite material
SG11201601777RA (en) Sliced assembly type container and method for manufacturing the same
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
EP3003390A4 (en) Anti-c10orf54 antibodies and uses thereof
SG10201408210UA (en) Energy harvesting device and method for forming the same
EP2968503A4 (en) Anti-hepcidin antibodies and uses thereof
IL244588A0 (en) fusion protein
GB201419614D0 (en) Magnetic core element, magnetic core module and an inductive component using the magnetic core module
IL240665A0 (en) Improved aluminum-magnesium-lithium alloys and methods for their production
PL2983012T3 (pl) Wieloenergetyczny wielodawkowy akcelerator, szybki układ kontrolny mający akcelerator i odpowiedni szybki sposób kontrolowania
EP3089951A4 (en) Ceramic and method for preparing the same
IL240474A0 (en) Cross-linking proteins that bind to cartilage
EP3038745A4 (en) Catalyst for preparing phosgene and method for preparing phosgene using the same
EP2796509B8 (en) Silicone composite particle and a method for preparing the same
EP3087010A4 (en) Container closure, container assembly and method for utilizing the same
EP3065774A4 (en) Anti-ccl17 antibodies
PL3087090T3 (pl) Ulepszenie białka fuzyjnego pestycydów
EP3041383A4 (en) Cover member and method for manufacturing the same
EP3052484A4 (en) Sulfonylindole derivatives and method for preparing the same
SG2013015540A (en) Unloading system for sand and the method thereof
EP3015455A4 (en) 4-benzyl-1-phenethyl-piperazine-2,6-dione preparation method, and intermediate and preparation method thereof
GB201305195D0 (en) Barrier system and ,ethod of assembling the same
GB201318660D0 (en) Ferritic alloys and methods for preparing the same